Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

By sjmartinez • March 21, 2024

Yuen MF, Fung S, Ma X, Nguyen TT, Hassanein T, Hann HW, Elkhashab M, Nahass RG, Park JS, Jacobson IM, Ayoub WS, Han SH, Gane EJ, Zomorodi K, Yan R, Ma J, Knox SJ, Stamm LM, Bonacini M, Weilert F, Ramji A, Bennett M, Ravendhran N, Chan S, Dieterich DT, Kwo PY, Schiff ER, Bae HS, Lalezari J, Agarwal K, Sulkowski MS. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses. JHEP Rep. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999. PMID: 38510983; PMCID: PMC10951643.

Tags: Antiviral, Cedars Sinai DoM, Core inhibitor, Digestive Diseases, Hepatitis, hepatitis B virus, Nucleos(t)ide reverse transcriptase inhibitor, Off-treatment, Open-label, Publications, Viral relapse

Early-Onset Hypertension and Sex-Specific Residual Risk for Cardiovascular Disease in Type 2 Diabetes

Ji H, Ebinger JE, Kwan AC, Reue K, Sullivan JC, Shyy J, Cheng S. Early-Onset Hypertension and Sex-Specific Residual Risk for Cardiovascular Disease in Type[...]

Time-to-Event Genome-Wide Association Study for Incident Cardiovascular Disease in People With Type 2 Diabetes

Kwak SH, Hernandez-Cancela RB, DiCorpo DA, Condon DE, Merino J, Wu P, Brody JA, Yao J, Guo X, Ahmadizar F, Meyer M, Sincan M, Mercader[...]

Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block

Lee YT, Tseng HR, Yang JD. Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block. Hepatology. 2024 Apr 19.[...]